https://www.hemato2026.com/
Congreso Hemato
LXVIII Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia (SEHH) y el XLII Congreso de la Sociedad Española de Trombosis y Hemostasia...
congresohemato
https://www.preprints.org/manuscript/202508.0301
Potential Impact of HLA DQB1*05 on Identical Sibling Hemato-Poietic Stem Cell Transplantation...
Background/Objectives: Human leukocyte antigens (HLA) are major determinants of successful allogeneic hem-atopoietic stem cell transplantation (allo-HSCT)....
https://www.mdpi.com/journal/hemato/sections/non_neoplastic_blood_disorders
Hemato | Section Non Neoplastic Blood Disorders
Hemato, an international, peer-reviewed Open Access journal.
hematosectionnonneoplasticblood
https://www.mdpi.com/1424-8247/17/1/106
Improving Drug Safety in Pediatric and Young Adult Patients with Hemato-Oncological Diseases: A...
The acquisition of relevant pediatric clinical safety data is essential to ensure tolerable drug therapies. Comparing the real number of Adverse Drug Reaction...
https://hematometabolism.science/
Hemato Metabolism
hematometabolism
https://punehaematologist.com/
Hematologist in Pune | Hemato-Oncologist in Pune | Dr. Chandrakant Lahane
Apr 22, 2025 - Dr. Chandrakant Lahane is a renowned hematologist and hemato-oncologist in Pune, specializing in blood disorders and oncology treatments.
hematologistpuneoncologistdr
https://www.mendeley.com/catalogue/cfda09a6-fbc0-3fbd-9dbb-1c9c4bd4e4e3/
CAR-T cells and allogeneic hemato... preview & related info | Mendeley
(2017) Liu et al. Immunotherapy. Relapsed/refractory acute lymphoblastic leukemia (ALL) has a low remission rate after chemotherapy, a high relapse rate and...
car t cellsrelated infoallogeneichematopreview
https://hemato2026.com/
Congreso Hemato
congresohemato
https://programa.hemato2025.com/
Hemato 25
hemato25
https://www.researchandmarkets.com/reports/5876164/hemato-oncology-testing-market-size-share-and
Hemato Oncology Testing Market Size, Share & Trends Analysis Report By Product (Assay Kits &...
The Hemato Oncology Testing Market, valued at USD 3.6B in 2024, is projected to reach USD 7.44B by 2030, growing at a 12.9% CAGR.